ArticleBritish journal of cancer2015

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.

B A Wilky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.